Literature DB >> 10382587

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes.

M P Hermans1, J C Levy, R J Morris, R C Turner.   

Abstract

AIMS/HYPOTHESIS: Adequate comparison of the relative performance of insulin sensitivity tests is not yet available. We compared the discrimination of four insulin sensitivity tests, commonly used in vivo, across a range of glucose tolerance.
METHODS: Normal (n = 7), impaired glucose tolerant (n = 8) and Type II (non-insulin-dependent) diabetic subjects (n = 9) had in random order two tests from the following: frequently sampled insulin-modified intravenous glucose tolerance test (FSIVGTT-MinMod); homeostasis model assessment (HOMA) and 2-h continuous infusion of glucose with model assessment (CIGMA) with immunoreactive or specific insulin; short insulin tolerance tests (ITT). The discriminatory power of tests was assessed by the ratio of the within-subject standard deviation to the underlying between-subject standard deviation (discriminant ratio - DR). The degree to which tests measured the same variable was assessed by comparing rank correlation with the maximum expected correlation given the imprecision of the tests. The unbiased lines of equivalence taking into account the precision of tests were constructed.
RESULTS: Reciprocal fasting plasma insulin (FPI(-1)), HOMA %S and 2-h CIGMA %S, had similar DRs with ITT being less informative. The FSIVGTT-MinMod analysis was able to assess 13 out of 24 subjects and had a performance similar to ITT. Using specific rather than immunoreactive insulin for HOMA-CIGMA did not improve the DR. Reciprocal fasting plasma insulin FPI(-1), HOMA %S, 2-h CIGMA %S and S(I) FSIVGTT intercorrelated more than 90% of the expected rank correlation given the imprecision of the tests, but ITT gave only limited correlation. CONCLUSION/
INTERPRETATION: The HOMA-CIGMA test with immunoreactive insulin provides similar information in distinguishing insulin sensitivity between subjects with normal glucose tolerance, those with impaired glucose tolerance and those with Type II diabetes as does FSIVGTT, whereas ITT is less informative.

Entities:  

Mesh:

Year:  1999        PMID: 10382587     DOI: 10.1007/s001250051215

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  48 in total

1.  Insulin resistance is not necessarily an essential element of metabolic syndrome.

Authors:  Rudruidee Karnchanasorn; Horng-Yi Ou; Lee-Ming Chuang; Ken C Chiu
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

2.  Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Takhar Kasumov; John M Edmison; Srinivasan Dasarathy; Carole Bennett; Rocio Lopez; Satish C Kalhan
Journal:  Metabolism       Date:  2010-09-23       Impact factor: 8.694

3.  Assessment of Glucose Control Metrics by Discriminant Ratio.

Authors:  Vanessa Moscardó; Pau Herrero; Monika Reddy; Nathan R Hill; Pantelis Georgiou; Nick Oliver
Journal:  Diabetes Technol Ther       Date:  2020-10       Impact factor: 6.118

Review 4.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

5.  No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.

Authors:  Jie Li; Xue Li; Emily Liu; Paul Copeland; Oliver Freudenreich; Donald C Goff; David C Henderson; Xueqin Song; Xiaoduo Fan
Journal:  Schizophr Res       Date:  2013-02-21       Impact factor: 4.939

6.  Insulin resistance is a risk factor for progression to type 1 diabetes.

Authors:  S Fourlanos; P Narendran; G B Byrnes; P G Colman; L C Harrison
Journal:  Diabetologia       Date:  2004-10-06       Impact factor: 10.122

7.  Association of insulin resistance with serum ferritin and aminotransferases-iron hypothesis.

Authors:  Jean Huang; Rudruidee Karnchanasorn; Horng-Yih Ou; Wei Feng; Lee-Ming Chuang; Ken C Chiu; Raynald Samoa
Journal:  World J Exp Med       Date:  2015-11-20

8.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

9.  Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease.

Authors:  Dokyoung Yoon; Seung Hwan Lee; Hye Soon Park; Ji Hoon Lee; Jin Seo Park; Kyung Hwan Cho; Seon Mee Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

10.  Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Authors:  David C Henderson; Xiaoduo Fan; Bikash Sharma; Paul M Copeland; Christina P C Borba; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Psychiatr Pract       Date:  2009-07       Impact factor: 1.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.